This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): thalidomide, Thalidomide Celgene (EU)
Thalomid is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration.
Another major target may be the ligase protein, cereblon (CRBN; http://www.nature.com/leu/journal/v26/n11/full/leu2012119a.html).
Deal Structure: In December 1998, EntreMed and Celgene announced the signing of a collaborative sublicensing agreement for the advancement of thalidomide drug development. Under the agreement, Celgene has acquired exclusive worldwide rights to EntreMed's patents and technology for thalidomide, as well as United States Food and Drug Administration (FDA) orphan drug designations achieved by EntreMed. EntreMed will receive royalty payments beginning immediately. Celgene will now have responsibility for present and future clinical research on thalidomide.
In December 2004, Celgene Corporation and Pharmion Corporation announced an expansion of their thalidomide development and commercialization collaboration. Following Celgene's October acquisition of Penn T, a worldwide supplier of thalidomide for both Celgene and Pharmion, Celgene and Pharmion have agreed to revise their Product Supply Agreement. The modified agreement will entail a one-time payment of $77 million to Celgene in return for a...See full deal structure in Biomedtracker
Partners: CASI Pharmaceuticals, Inc. DRI Capital Inc.
Additional information available to subscribers only: